Advanced search
1 file | 206.32 KB

The oncologic role of local treatment in primary metastatic prostate cancer

(2015) WORLD JOURNAL OF UROLOGY. 33(6). p.755-761
Author
Organization
Abstract
To determine the oncologic benefit or otherwise of local treatment of the prostate in patients with primary metastatic prostate cancer. A review of the literature was performed in April 2014 using the Medline/PubMed database. Studies were identified using the search terms "prostate cancer," "metastatic," "metastasis," "high risk," "radiation therapy," "radiotherapy" and "prostatectomy" from 1990 until April, 2014. Articles were also identified through searches of references of these articles. Retrospective series and population-based data suggest that the use of local treatment of the prostate in patients with primary metastatic prostate cancer may improve cancer-specific survival and overall survival compared with treating these patients with androgen deprivation therapy alone. The clinical outcome in metastatic prostate cancer is largely determined by the extent of lymph node involvement and overall metastatic burden. Contemporary data are lacking to recommend one alternative of local therapy (radiotherapy or radical prostatectomy) over the other. The primary limitation of this literature review is the lack of published randomized trial assessing the role of local treatment in addition to systemic therapy. Local treatment appears to improve oncologic outcomes in metastatic prostate cancer patients. Nevertheless, due to the lack of high-quality evidence, its role needs to be confirmed in future prospective trials. The selection of ideal candidates and optimal treatment alternative (radiotherapy, radical prostatectomy or other) warrants further investigation.
Keywords
Metastatic, Prostate cancer, Metastasis, High risk, Local treatment, Outcomes, Radiation therapy, Radiotherapy, Radical prostatectomy, ANDROGEN-DEPRIVATION THERAPY, PHASE-III TRIAL, RADICAL PROSTATECTOMY, RADIATION-THERAPY, ENDOCRINE TREATMENT, MORTALITY OUTCOMES, RANDOMIZED-TRIAL, ANTIGEN ERA, FOLLOW-UP, RADIOTHERAPY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 206.32 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Ghadjar, Pirus, Alberto Briganti, Pieter De Visschere, Jurgen J Fütterer, Gianluca Giannarini, Henrik Isbarn, Piet Ost, et al. 2015. “The Oncologic Role of Local Treatment in Primary Metastatic Prostate Cancer.” World Journal of Urology 33 (6): 755–761.
APA
Ghadjar, P., Briganti, A., De Visschere, P., Fütterer, J. J., Giannarini, G., Isbarn, H., Ost, P., et al. (2015). The oncologic role of local treatment in primary metastatic prostate cancer. WORLD JOURNAL OF UROLOGY, 33(6), 755–761.
Vancouver
1.
Ghadjar P, Briganti A, De Visschere P, Fütterer JJ, Giannarini G, Isbarn H, et al. The oncologic role of local treatment in primary metastatic prostate cancer. WORLD JOURNAL OF UROLOGY. 2015;33(6):755–61.
MLA
Ghadjar, Pirus et al. “The Oncologic Role of Local Treatment in Primary Metastatic Prostate Cancer.” WORLD JOURNAL OF UROLOGY 33.6 (2015): 755–761. Print.
@article{6843184,
  abstract     = {To determine the oncologic benefit or otherwise of local treatment of the prostate in patients with primary metastatic prostate cancer. 
A review of the literature was performed in April 2014 using the Medline/PubMed database. Studies were identified using the search terms "prostate cancer," "metastatic," "metastasis," "high risk," "radiation therapy," "radiotherapy" and "prostatectomy" from 1990 until April, 2014. Articles were also identified through searches of references of these articles. 
Retrospective series and population-based data suggest that the use of local treatment of the prostate in patients with primary metastatic prostate cancer may improve cancer-specific survival and overall survival compared with treating these patients with androgen deprivation therapy alone. The clinical outcome in metastatic prostate cancer is largely determined by the extent of lymph node involvement and overall metastatic burden. Contemporary data are lacking to recommend one alternative of local therapy (radiotherapy or radical prostatectomy) over the other. The primary limitation of this literature review is the lack of published randomized trial assessing the role of local treatment in addition to systemic therapy. 
Local treatment appears to improve oncologic outcomes in metastatic prostate cancer patients. Nevertheless, due to the lack of high-quality evidence, its role needs to be confirmed in future prospective trials. The selection of ideal candidates and optimal treatment alternative (radiotherapy, radical prostatectomy or other) warrants further investigation.},
  author       = {Ghadjar, Pirus and Briganti, Alberto and De Visschere, Pieter and Fütterer, Jurgen J and Giannarini, Gianluca and Isbarn, Henrik and Ost, Piet and Sooriakumaran, Prasanna and Surcel, Christian I and Van den Bergh, Roderick CN and Van Oort, Inge M and Yossopowitch, Ofer and Ploussard, Guillaume},
  issn         = {0724-4983},
  journal      = {WORLD JOURNAL OF UROLOGY},
  keywords     = {Metastatic,Prostate cancer,Metastasis,High risk,Local treatment,Outcomes,Radiation therapy,Radiotherapy,Radical prostatectomy,ANDROGEN-DEPRIVATION THERAPY,PHASE-III TRIAL,RADICAL PROSTATECTOMY,RADIATION-THERAPY,ENDOCRINE TREATMENT,MORTALITY OUTCOMES,RANDOMIZED-TRIAL,ANTIGEN ERA,FOLLOW-UP,RADIOTHERAPY},
  language     = {eng},
  number       = {6},
  pages        = {755--761},
  title        = {The oncologic role of local treatment in primary metastatic prostate cancer},
  url          = {http://dx.doi.org/10.1007/s00345-014-1347-9},
  volume       = {33},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: